Skip to main content
. 2017 Oct 17;36:146. doi: 10.1186/s13046-017-0610-5

Table 1.

PAK5 and p65 staining and clinicopathologic characteristics of breast cancer patients

PAK5 staining (n = 129) p65 staining (n = 119)
Variables Low (%) High (%) Total P value Low (%) High (%) Total P value
Age
 < 50 years 14 (38.9) 22 (61.1) 36 0.558 13 (40.6) 19 (59.4) 32 0.409
 ≥ 50 years 42 (45.2) 51 (54.8) 93 44 (50.6) 43 (49.4) 87
pT status
 pT0-pT1 23 (69.7) 10 (30.3) 33 0.000 21 (63.6) 12 (36.4) 33 0.039
 pT2- pT4 29 (30.9) 65 (69.1) 94 34 (40.5) 50 (59.5) 84
pN status
 pN0 34 (50.7) 33 (49.3) 67 0.011 36 (59.0) 25 (41.0) 61 0.018
 pN1- pN3 17 (27.9) 44 (72.1) 61 21 (36.8) 36 (63.2) 57
TNM stage
 I~II 32 (50.8) 31 (49.2) 63 0.03 36 (59.0) 25 (41.0) 61 0.018
 I~III 11 (32.4) 23 (67.6) 34 14 (43.8) 18 (56.2) 32
 III 5 (21.7) 18 (78.3) 23 4 (22.2) 14 (51.4) 18

pT pathological tumour size, pN pathological lymph node metastasis, TNM Tumor node metastasis